MedTrace Logo

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

NCT00352417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-07-27

Study results available
· View outcomes & findings →

Summary

This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy

Conditions

Interventions

DRUG

VIA-2291

100 mg, oral dosing, 1 time daily for 12 weeks

DRUG

Placebo

oral dosing, 1 time daily for 12 weeks

Sponsors & Collaborators

  • Tallikut Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rebecca Taub, MD · VIA Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352417 on ClinicalTrials.gov